Contact Us
Drug Search Results
More Filters [+]

Tradipitant

Alternative Names: tradipitant, vly-686, ly686017
Latest Update: 2024-12-11
Latest Update Note: Clinical Trial Update

Product Description

Tradipitant (VLY-686) is a potent selective inhibitor of NK1R and is hypothesized to treat gastroparesis by acting centrally in the nausea-vomiting centers of the brain and peripherally in the smooth muscle of the intestines.

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vanda
Company Location: WASHINGTON DC 20037
Company CEO: Mihael H. Polymeropoulos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tradipitant

Countries in Clinic: Belgium, Germany, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Communicable Diseases|Coronavirus Infections|Gastroparesis|Motion Sickness

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
VP-VLY-686-3304

P3

Unknown Status

Gastroparesis

2025-12-31

Motion Delos

P3

Recruiting

Motion Sickness

2025-04-30

67%
VP-VLY-686-3301

P3

Recruiting

Gastroparesis

2024-12-01

33%
Motion Serifos

P3

Completed

Motion Sickness

2024-04-06

Recent News Events

Date

Type

Title

01/21/2025

News Article

 Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market Transformation - Technavio

11/26/2024

News Article

 Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market Trends - Technavio

11/05/2024

News Article

 Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend Insights - Technavio

10/14/2024

News Article

 Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

02/05/2024

PubMed

 Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing: A Prespecified Secondary Analysis of the HCS Randomized Clinical Trial.

01/17/2024

PubMed

 The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial.

09/07/2023

PubMed

 Diabetic Gastroparesis and its Emerging Therapeutic Options: A Narrative Review of the Literature.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions